跳至主要内容

Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"

 On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list.

Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!  This is the Science and Technology Commission of Shanghai Municipality's high recognition of Medicilon's technological innovation and R&D capabilities, and is also a spur and incentive for Medicilon to continuously improve its service levels.

2023 Shanghai Professional Technical Service Platform.webp

The Shanghai professional technical service platform is an important part of Shanghai's scientific and technological innovation service system. It is a scientific research entity built on the basis of enterprises, scientific research institutes, universities or other institutions with scientific and technological innovation capabilities.  It is oriented to the needs of scientific and technological innovation and economic and social development, and integrates various scientific and technological resources play a fundamental functional role in reducing the cost of scientific and technological innovation, promoting innovation-driven development, and creating a scientific and technological innovation ecosystem.

The Nucleic Acid Drug R&D Service Platform selected by Medicilon this time is an integrated and comprehensive platform integrating drug discovery, production and preclinical research.  Based on rigorous scientific attitudes, open technology platforms, advanced instruments and equipment, as well as one-stop services for nucleic acid drug discovery, screening and preclinical research, it can shorten the research and development cycle, improve drug research and development efficiency, reduce costs, and promote new drugs to quickly enter the clinical stage.

Technological innovation is not achieved in a day, but comes from years of R&D investment and research.  As a one-stop biopharmaceutical preclinical R&D service platform in China, Medicilon has always integrated technological innovation into development since its establishment nearly 20 years ago.  Medicilon has accumulated rich R&D experience in the fields of ADC, small nucleic acids, PROTAC, and GLP-1.  Medicilon has served more than 50 ADC clients and currently has more than 30 projects under development, has served more than 40 small nucleic acid clients and has more than 20 projects under development, has served more than 30 PROTAC-related customers and nearly 20 projects are under development, and has also helped 8 GLP-1 related drugs obtain clinical approval.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文